- Home
- TRX vs WHWK Comparison
TRX vs WHWK Comparison
Compare TRX & WHWK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TRX
- WHWK
- Stock Information
- Founded
- TRX 1990
- WHWK 2007
- Country
- TRX Canada
- WHWK United States
- Employees
- TRX N/A
- WHWK N/A
- Industry
- TRX
- WHWK Biotechnology: Pharmaceutical Preparations
- Sector
- TRX
- WHWK Health Care
- Exchange
- TRX Nasdaq
- WHWK Nasdaq
- Market Cap
- TRX 95.9M
- WHWK 82.4M
- IPO Year
- TRX N/A
- WHWK N/A
- Fundamental
- Price
- TRX $0.52
- WHWK $1.95
- Analyst Decision
- TRX Strong Buy
- WHWK
- Analyst Count
- TRX 1
- WHWK 0
- Target Price
- TRX $1.10
- WHWK N/A
- AVG Volume (30 Days)
- TRX 1.3M
- WHWK 122.8K
- Earning Date
- TRX 07-15-2025
- WHWK 11-15-2025
- Dividend Yield
- TRX N/A
- WHWK N/A
- EPS Growth
- TRX N/A
- WHWK N/A
- EPS
- TRX N/A
- WHWK N/A
- Revenue
- TRX $47,731,000.00
- WHWK $21,596,000.00
- Revenue This Year
- TRX $23.64
- WHWK N/A
- Revenue Next Year
- TRX $51.77
- WHWK N/A
- P/E Ratio
- TRX $498.50
- WHWK N/A
- Revenue Growth
- TRX 29.98
- WHWK N/A
- 52 Week Low
- TRX $0.27
- WHWK $1.39
- 52 Week High
- TRX $0.55
- WHWK $3.81
- Technical
- Relative Strength Index (RSI)
- TRX 80.75
- WHWK 59.78
- Support Level
- TRX $0.51
- WHWK $1.80
- Resistance Level
- TRX $0.55
- WHWK $2.02
- Average True Range (ATR)
- TRX 0.03
- WHWK 0.10
- MACD
- TRX 0.01
- WHWK 0.02
- Stochastic Oscillator
- TRX 84.35
- WHWK 67.86
About TRX TRX Gold Corporation
TRX Gold Corp is a mineral resource company. It is engaged in the acquisition of interests and the exploration of natural resource properties. Its mineral properties are located in the United Republic of Tanzania. The company's main area of interest has been in the exploration and development of gold properties. It is focused on the Buckreef Gold Project which comprises five prospects, namely Buckreef, Bingwa, Tembo, Eastern Porphyry, and Buziba.
About WHWK Whitehawk Therapeutics Inc. Common Stock
Whitehawk Therapeutics Inc is a preclinical stage oncology therapeutics. The company is engaged in applying technologies to established tumor biology to efficiently deliver improved cancer treatments. The company's three-asset ADC portfolio is engineered to overcome the limitations of first-generation predecessors to deliver a meaningful impact for patients with difficult-to-treat cancers.